Summit Therapeutics opened lower at $16.03, compared with its previous close of $16.20. In the last trading session, the stock traded between $15.71 and $16.43. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Summit Therapeutics is now worth
$ 305.52
giving a profit of
$ 205.52 (205.52%)
Note: Past profits do not guarantee future returns.
Rating from 13 Analysts
Today's Change
$-0.44 (-2.69%)
Day High
$16.43
Day Low
$15.71
Day Open
$16.03
Prev Close
$16.20
Volume
14,78,010
1W Return
1.36%
1M Return
-3.84%
3M Return
23.21%
6M Return
-24.32%
1Y Return
-15.51%
Market Cap ($ Mn)
12,608
PE Ratio
-
PB Ratio
17.29
PEG Ratio
-
ROE
-292.77%
ROCE
-286.88%
EPS (TTM)
$-0.27
1 Week
1.36%
1 Month
-3.84%
3 Months
23.21%
6 Months
-24.32%
9 Months
2.37%
Summit launches Phase II/III BTC trial with ECOG-ACRIN
Summit Therapeutics initiates EA2251, a Phase II/III study of ivonescimab in first-line biliary tract cancer. Collaboration with ECOG-ACRIN targets US patients; site activations begin Q4 2026. Primary endpoint is overall survival, comparing ivonescimab plus chemo to pembrolizumab or durvalumab. Total Phase III studies involving ivonescimab rises to 17, including two cooperative group-sponsored trials.
9 days agoSummit adds Daiichi Sankyo to ivonescimab clinical collaboration
Summit Therapeutics enters a three-way clinical collaboration with AstraZeneca and Daiichi Sankyo. The partnership evaluates ivonescimab combined with Datroway, a TROP2-directed ADC. Initial focus is a Phase III study in first-line triple-negative breast cancer (TNBC). Collaboration expands Summit's program beyond non-small cell lung cancer indications.
28 days agoSummit Therapeutics to present ivonescimab Phase III data at ESMO 2026
Summit Therapeutics will present HARMONi-GI1 Phase III data at ESMO 2026. Ivonescimab plus chemo showed significant overall survival benefit vs durvalumab. First Phase III OS benefit shown for anti-PD-(L)1 combination in biliary tract cancer. Data generated by Akeso; presentation scheduled for October 25, 2026.
1mo agoSummit Therapeutics stock rises 6% as partner Akeso reports positive lung cancer trial data
Summit Therapeutics (NASDAQ: SMMT) shares rose 6.25% to $18.65 on Monday. Partner Akeso Inc. reported Phase 3 HARMONi-2 trial data for ivonescimab in lung cancer. Ivonescimab showed a median overall survival of 30.8 months vs 22.6 months for pembrolizumab. Treatment reduced death risk by 27% overall, with up to 42% reduction in high PD-L1 patients.
1mo agoAkeso reports OS benefit for ivonescimab in HARMONi-2 NSCLC study
Akeso reported positive overall survival results for ivonescimab in the Phase III HARMONi-2 study. Ivonescimab showed statistically significant improvement vs pembrolizumab in PD-L1-positive NSCLC. Previous primary analysis showed HR of 0.51 for progression-free survival. Drug is approved in China but remains investigational in Summit's license territories.
1mo agoAkeso ivonescimab beats durvalumab in Phase III BTC trial
Ivonescimab plus chemo showed OS superiority vs durvalumab plus chemo in Phase III BTC trial. Study met secondary endpoints of PFS and ORR in interim analysis. First Phase III trial to beat global gold standard in advanced biliary tract cancer. Drug is approved in China for NSCLC but investigational in US and Europe.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $540.00 | +1.95% | $1,36,868.94M | 31.55 | |
| $61.07 | +2.12% | $1,31,639.87M | 14.39 | |
| $222.76 | +4.01% | $88,933.81M | - | |
| $818.77 | +0.68% | $82,808.76M | 19.64 | |
| $897.85 | +0.68% | $56,462.20M | 38.99 | |
| $371.56 | -0.48% | $40,792.43M | 65.60 | |
| $190.27 | +0.82% | $40,781.71M | - | |
| $56.49 | -1.40% | $35,253.15M | 26.24 | |
| $65.93 | +1.71% | $29,357.11M | 32.37 | |
| $37.52 | +1.10% | $27,101.56M | - | |
| $111.59 | +15.07% | $24,369.25M | - | |
| $116.80 | -0.06% | $23,675.13M | 15.85 |
An investment of $100 made 5 years ago in Summit Therapeutics is now worth
$ 305.52
giving a profit of
$ 205.52 (205.52%)
Note: Past profits do not guarantee future returns.
